The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Addressing cardiovascular AEs associated with BTKi treatment in patients with CLL
Lee Greenberger, PhD, Leukemia & Lymphoma Society, New York, NY, addresses cardiovascular adverse events (AEs) related to BTK inhibitors (BTKi) in the treatment of patients with chronic lymphocytic leukemia (CLL). There are multiple BTKi available, including those with lower cardiovascular toxicity, such as acalabrutinib and zanubrutinib, so physicians have various avenues to ensure the benefits of BTKi treatment are optimized. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
